JP6982578B2 - 細胞培養培地 - Google Patents

細胞培養培地 Download PDF

Info

Publication number
JP6982578B2
JP6982578B2 JP2018556896A JP2018556896A JP6982578B2 JP 6982578 B2 JP6982578 B2 JP 6982578B2 JP 2018556896 A JP2018556896 A JP 2018556896A JP 2018556896 A JP2018556896 A JP 2018556896A JP 6982578 B2 JP6982578 B2 JP 6982578B2
Authority
JP
Japan
Prior art keywords
acid
medium
lithium
integrin
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514383A (ja
JP2019514383A5 (https=
Inventor
ティー．ルバー クリストファー
ダブリュ．ワイ．シェン マイケル
タオ イーウェン
ユージーン ムーラリー，ザ フォース ヒュー
Original Assignee
タンベックス バイオファーマ ユーエスエー，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンベックス バイオファーマ ユーエスエー，インコーポレイティド filed Critical タンベックス バイオファーマ ユーエスエー，インコーポレイティド
Publication of JP2019514383A publication Critical patent/JP2019514383A/ja
Publication of JP2019514383A5 publication Critical patent/JP2019514383A5/ja
Priority to JP2021062942A priority Critical patent/JP2021112191A/ja
Application granted granted Critical
Publication of JP6982578B2 publication Critical patent/JP6982578B2/ja
Priority to JP2023101764A priority patent/JP2023126248A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2018556896A 2016-04-26 2017-04-26 細胞培養培地 Active JP6982578B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021062942A JP2021112191A (ja) 2016-04-26 2021-04-01 細胞培養培地
JP2023101764A JP2023126248A (ja) 2016-04-26 2023-06-21 細胞培養培地

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662327964P 2016-04-26 2016-04-26
US62/327,964 2016-04-26
PCT/US2017/029566 WO2017189679A1 (en) 2016-04-26 2017-04-26 Cell culture medium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021062942A Division JP2021112191A (ja) 2016-04-26 2021-04-01 細胞培養培地

Publications (3)

Publication Number Publication Date
JP2019514383A JP2019514383A (ja) 2019-06-06
JP2019514383A5 JP2019514383A5 (https=) 2020-06-18
JP6982578B2 true JP6982578B2 (ja) 2021-12-17

Family

ID=60089387

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018556896A Active JP6982578B2 (ja) 2016-04-26 2017-04-26 細胞培養培地
JP2021062942A Pending JP2021112191A (ja) 2016-04-26 2021-04-01 細胞培養培地
JP2023101764A Pending JP2023126248A (ja) 2016-04-26 2023-06-21 細胞培養培地

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021062942A Pending JP2021112191A (ja) 2016-04-26 2021-04-01 細胞培養培地
JP2023101764A Pending JP2023126248A (ja) 2016-04-26 2023-06-21 細胞培養培地

Country Status (7)

Country Link
US (2) US10703800B2 (https=)
EP (1) EP3448982A4 (https=)
JP (3) JP6982578B2 (https=)
AU (2) AU2017255538B2 (https=)
CA (1) CA3019400A1 (https=)
TW (1) TWI734775B (https=)
WO (1) WO2017189679A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3635093A1 (en) * 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
BR112020000127A2 (pt) * 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
CN108823267B (zh) * 2018-06-25 2020-05-08 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法
JP7388722B2 (ja) * 2018-08-10 2023-11-29 国立大学法人 東京大学 アルギン酸中空マイクロファイバ
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
US20230166200A1 (en) * 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
WO2023058051A1 (en) * 2021-10-04 2023-04-13 Dr. Reddy's Laboratories Limited Process to produce a pharmaceutical composition
CN120917038A (zh) * 2023-03-23 2025-11-07 伊莱利利公司 生产含有Fc的蛋白质的方法
CN116814532B (zh) * 2023-07-10 2025-02-11 上海迈邦生物科技有限公司 一种用于哺乳动物细胞培养基的脂类复合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378612A (en) 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
CL2007002404A1 (es) * 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
PT2164866E (pt) * 2007-05-29 2014-08-04 Angiochem Inc Polipéptidos de tipo aprotinina para administrar agentes conjugados com os mesmos aos tecidos
JP2009017847A (ja) * 2007-07-13 2009-01-29 Nipro Corp 細胞培養培地の製造方法及び細胞培養培地
DK2491385T3 (en) * 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
EP2531592A1 (en) * 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
MX368546B (es) 2011-05-20 2019-10-07 Alderbio Holdings Llc Producción en alta pureza de proteínas multi-subunitarias tales como anticuerpos en microbios transformados tal como pichia pastoris.
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
KR101519478B1 (ko) 2013-07-25 2015-05-12 한국환경정책평가연구원 진공관과 냉각채널이 결합된 막 증류 수처리 장치
KR20160125352A (ko) 2013-12-20 2016-10-31 이센셜 파마수티컬스 엘엘씨 세포 배양용 배지
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
US10227559B2 (en) 2014-04-10 2019-03-12 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
KR101625595B1 (ko) * 2014-04-30 2016-05-31 한국과학기술원 재조합 단백질 생산 증가를 위한 염화리튬을 포함하는 세포 배양용 배지 조성물 및 이의 용도
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基

Also Published As

Publication number Publication date
AU2017255538A1 (en) 2018-10-11
JP2021112191A (ja) 2021-08-05
WO2017189679A1 (en) 2017-11-02
JP2019514383A (ja) 2019-06-06
US10703800B2 (en) 2020-07-07
TW201741454A (zh) 2017-12-01
EP3448982A1 (en) 2019-03-06
TWI734775B (zh) 2021-08-01
TW202140776A (zh) 2021-11-01
US20200385444A1 (en) 2020-12-10
AU2017255538B2 (en) 2022-03-03
JP2023126248A (ja) 2023-09-07
CA3019400A1 (en) 2017-11-02
EP3448982A4 (en) 2020-02-26
US12173049B2 (en) 2024-12-24
US20170305999A1 (en) 2017-10-26
AU2022203779A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP6982578B2 (ja) 細胞培養培地
JP7034991B2 (ja) 改良型細胞培養培地
KR101828624B1 (ko) 개선된 세포 배양 방법
KR102255902B1 (ko) 배양배지의 최적화를 통한 재조합 단백질의 갈락토오스화를 조절하는 방법
KR101644954B1 (ko) 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법
AU2011246502A1 (en) Improved cell cultivation process
EP3083933A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
JP7551760B2 (ja) 哺乳動物細胞培養プロセス
JP2022536658A (ja) 抗体生産のための細胞培養方法及び組成物
US10526631B1 (en) Method of reducing serine for asparagine misincorporation
KR101318498B1 (ko) 재조합 단백질의 생산성 향상을 위한 배양용 배지 첨가용 조성물
TWI920111B (zh) 細胞培養基
HK1238298A1 (en) Cell culture process for producing a protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200427

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210401

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210402

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210521

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211119

R150 Certificate of patent or registration of utility model

Ref document number: 6982578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250